Aprogen Biologics Inc. (KRX:003060)
South Korea · Delayed Price · Currency is KRW 2,075.00
-80.00 (-3.71%)
Aug 12, 2026, 1:01 PM KST
Aprogen Biologics Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 77,998 | 73,226 | 67,378 | 87,364 | 65,190 | 56,482 |
Revenue Growth | 13.67% | 8.68% | -22.88% | 34.01% | 15.42% | 5.93% |
Gross Profit Gross Profit Growth | -24,622 | -27,354 | -7,846 | -11,974 | 25,810 | 24,875 |
Operating Income Operating Income Growth | -116,821 | -122,889 | -58,577 | -70,690 | -4,204 | -3,975 |
Net Income Net Income Growth | -131,207 | -170,331 | -104,979 | -118,270 | 12,639 | 8,103 |
Earnings Per Share EPS Growth | -9961.73 | -12931.73 | -12525.00 | -28125.00 | 4650.00 | 3000.00 |
EPS Growth | - | - | - | - | 55.00% | -42.86% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Business Division Pharmaceutical Business Division Growth | 57,530 | 57,186 | 57,571 | 62,954 | 64,743 | 55,744 |
Bio Business Division Bio Business Division Growth | 2,671 | 5,575 | 9,448 | 16,870 | 274.43 | - |
Semiconductor Business Division Semiconductor Business Division Growth | - | 9,636 | - | - | - | - |
Other Sales Other Sales Growth | 979.05 | 829.33 | 358.95 | 812.16 | - | - |
Total Total Growth | 77,998 | 73,226 | 67,378 | 87,364 | 65,190 | 56,482 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 50,102 | 51,633 | 38,319 | 10,053 | 99,074 | 124,935 |
Total Debt Total Debt Growth | 227,155 | 228,796 | 154,017 | 180,997 | 134,738 | 2,481 |
Net Cash (Debt) Net Cash Growth | -177,053 | -177,163 | -115,698 | -170,944 | -35,664 | 122,454 |
Net Cash Growth | - | - | - | - | - | -39.41% |
Net Cash Per Share Net Cash Per Share Growth | -13442.12 | -13450.44 | -13803.94 | -40646.99 | -13234.78 | 46085.02 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -36,254 | -38,233 | -30,996 | -33,651 | 25,728 | -6,227 |
Capital Expenditures CapEx Growth | -5,563 | -9,625 | -15,264 | -28,088 | -1,284 | -796.19 |
Free Cash Flow Free Cash Flow Growth | -41,817 | -47,857 | -46,261 | -61,739 | 24,444 | -7,023 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -31.57% | -37.35% | -11.64% | -13.71% | 39.59% | 44.04% |
Operating Margin | -149.77% | -167.82% | -86.94% | -80.92% | -6.45% | -7.04% |
Pretax Margin | -167.81% | -231.31% | -155.81% | -129.78% | 22.83% | 17.41% |
Profit Margin | -168.22% | -232.61% | -155.81% | -135.38% | 19.39% | 14.34% |
FCF Margin | -53.61% | -65.36% | -68.66% | -70.67% | 37.50% | -12.43% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 15.86 | 44.52 |
P/FCF Ratio | - | - | - | - | 8.20 | - |
PS Ratio | 0.65 | 1.40 | 1.94 | 2.18 | 3.08 | 6.39 |